3 Drugs Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 51 points (-0.3%) at 18,140 as of Monday, May 11, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,286 issues advancing vs. 1,726 declining with 119 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.2%. Top gainers within the industry include Bristol-Myers Squibb Company ( BMY), up 1.4%, Teva Pharmaceutical Industries ( TEVA), up 1.1%, GlaxoSmithKline ( GSK), up 1.3%, Eli Lilly and ( LLY), up 0.7% and AstraZeneca ( AZN), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $0.41 (0.6%) to $65.65 on light volume. Thus far, 3.3 million shares of AbbVie exchanged hands as compared to its average daily volume of 12.4 million shares. The stock has ranged in price between $65.08-$65.80 after having opened the day at $65.19 as compared to the previous trading day's close of $65.24.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $103.0 billion and is part of the health care sector. Shares are down 1.1% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full AbbVie Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Actavis ( ACT) is up $10.27 (3.5%) to $303.09 on heavy volume. Thus far, 2.7 million shares of Actavis exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $300.39-$305.77 after having opened the day at $305.72 as compared to the previous trading day's close of $292.82.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. Actavis has a market cap of $112.8 billion and is part of the health care sector. Shares are up 13.8% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Gilead ( GILD) is up $1.02 (1.0%) to $104.87 on average volume. Thus far, 4.3 million shares of Gilead exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $104.00-$105.15 after having opened the day at $104.19 as compared to the previous trading day's close of $103.85.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $151.0 billion and is part of the health care sector. Shares are up 10.2% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here